SwaroopAChewEYRickmanCBAbecasisGR. Unraveling a multifactorial late-onset disease: from genetic susceptibility to disease mechanisms for age-related macular degeneration. Annu Rev Genomics Hum Genet. 2009;10:19–43. doi:10.1146/annurev.genom.9.081307.164350.
2.
SobrinLSeddonJM. Nature and nurture—genes and environment—predict onset and progression of macular degeneration. Prog Retin Eye Res. 2014;40:1–15. doi:10.1016/j.preteyeres.
3.
SeddonJMFrancisPJGeorgeSSchultzDWRosnerBKleinML. Association of CFH Y402H and LOC387715 A69S with progression of age-related macular degeneration. JAMA. 2007;297(16):1793–1800.
4.
SeddonJMReynoldsRMallerJFagernessJADalyMJRosnerB. Prediction model for prevalence and incidence of advanced age-related macular degeneration based on genetic, demographic, and environmental variables. Invest Ophthalmol Vis Sci. 2009;50(5):2044–2053. doi:10.1167/iovs.08-3064.
5.
SeddonJMReynoldsRYuYDalyMJRosnerB. Risk models for progression to advanced age-related macular degeneration using demographic, environmental, genetic, and ocular factors. Ophthalmol. 2011;118(11):2203–2211. doi:10.1016/j.ophtha.2011.04.029.
6.
KleinMLFrancisPJFerrisFLIIIHamonSCClemonsTE. Risk assessment model for development of advanced age-related macular degeneration. Arch Ophthalmol. 2011;129(12):1543–1550. doi:10.1001/archophthalmol.2011.216.
7.
YuYReynoldsRRosnerBDalyMJSeddonJM. Prospective assessment of genetic effects on progression to different stages of age-related macular degeneration using multistate Markov models. Invest Ophthalmol Vis Sci. 2012;53(3):1548–1556. doi:10.1167/iovs.11-8657.
8.
PerleeLTBansalATGehrsK. Inclusion of genotype with fundus phenotype improves accuracy of predicting choroidal neovascularization and geographic atrophy. Ophthalmol. 2013;120(9):1880–1892. doi:10.1016/j.ophtha.2013.02.007.
9.
SeddonJMSilverREKwongMRosnerB. Risk prediction for progression of macular degeneration: 10 common and rare genetic variants, demographic, environmental, and macular covariates. Invest Ophthalmol Vis Sci. 2015;56(4):2192–2202. doi:10.1167/iovs.14-15841.
10.
Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol. 2001;119(10):1417–1436.
11.
KleinMLFerrisFL3rdArmstrongJ; AREDS Research Group. Retinal precursors and the development of geographic atrophy in age-related macular degeneration. Ophthalmol. 2008;115(6):1026–1031.
12.
FerrisFLDavisMDClemonsTE; Age-Related Eye Disease Study Research Group. A simplified severity scale for age-related macular degeneration: AREDS report no. 18. Arch Ophthalmol. 2005;123(11):1570–1574.
13.
FauserSLambrouGN. Genetic predictive biomarkers of anti-VEGF treatment response in patients with neovascular age-related macular degeneration. Surv Ophthalmol. 2015;60(2):138–152. doi:10.1016/j.survophthal.2014.11.002.
14.
LoteryAJGibsonJCreeAJ; Alternative Treatments to Inhibit VEGF in Patients with Age-Related Choroidal Neovascularisation (IVAN) Study Group. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age-related macular degeneration in the IVAN Study. Ophthalmol. 2013;120(2):2637–2643. doi:10.1016/j.ophtha.2013.07.046.
15.
HagstromSAYingGSPauerGJ; Comparison of AMD Treatment Trials Research Group. Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmol. 2013;120(3):593–599.
16.
HagstromSAYingGSPauerGJ; Comparison of Age-Related Macular Degeneration Treatments Trials Research Group. VEGFA and VEGFR2 gene polymorphisms and response to anti-vascular endothelial growth factor therapy: comparison of age-related macular degeneration treatments trials (CATT). JAMA Ophthalmol. 2014;132(5):521–527.
17.
ShahARWilliamsSBaumalCRRosnerBDukerJSSeddonJM. Predictors of response to intravitreal anti-vascular endothelial growth factor treatment of age-related macular degeneration. Am J Ophthalmol. 2016;163:154–166.e8. doi:10.1016/j.ajo.2015.11.033.
18.
KleinMLFrancisPJRosnerB. CFH and LOC387715/ARMS2 genotypes and treatment with antioxidants and zinc for age-related macular degeneration. Ophthalmol. 2008;115(6):1019–1025. doi:10.1016/j.ophtha.2008.01.036.
19.
SeddonJSilverRRosnerB. Response to AREDS supplements according to genetic factors: survival analysis approach using the eye as the unit of analyses. Br J Ophthalmol. In press.
20.
AwhCCHawkenSZankeBW. Treatment response to antioxidants and zinc based on CFH and ARMS2 genetic risk allele number in the Age-Related Eye Disease Study. Ophthalmol. 2015;122(1):162–169. doi:10.1016/j.ophtha.2014.07.049.
21.
AwhCCLaneAMHawkenSZankeBKimIK. CFH and ARMS2 genetic olymorphisms predict response to antioxidants and zinc in patients with age-related macular degeneration. Ophthalmol. 2013;120(11):2317–2323. doi:10.1016/j.ophtha.2013.07.039.
22.
GailMSimonR. Testing for qualitative interactions between treatment effects and patient subsets. Biometrics. 1985;41(2):361–372.
23.
YusufSWittesJProbstfieldJTyrolerHA. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA. 1991;266(1):93–98.
24.
WittesJMuschDC. Should we test for genotype in deciding on age-related eye disease study supplementation?Ophthalmol. 2015;122(1):3–5. doi:10.1016/j.ophtha.2014.10.023.
25.
LeeKLMcNeerJFStarmerCFHarrisPJRosatiRA. Clinical judgment and statistics. Lessons from a simulated randomized trial in coronary artery disease. Circulation. 1980;61(3):508–515.
26.
ChewEYKleinMLClemonsTE; Age-Related Eye Disease Study Research Group. No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38. Ophthalmol. 2014;121(11):2173–2180. doi:10.1016/j.ophtha.2014.05.008.
27.
ChewEYKleinMLClemonsTEAgronEAbecasisGR. Genetic testing in persons with age-related macular degeneration and the use of the AREDS supplements: to test or not to test?Ophthalmol. 2015;122(1):212–215. doi:10.1016/j.ophtha.2014.10.012.
28.
BuitendijkGHAminNHofmanAvan DuijnCMVingerlingJRKlaverCC. Direct-to-consumer personal genome testing for age-related macular degeneration. Invest Ophthalmol Vis Sci. 2014;55(10):6167–6174. doi:10.1167/iovs.14-15142.
